Kamada Ltd. (KMDA)
KMDANASDAQ-GSBiotechnology: Pharmaceutical Preparations
$8.04
+0.3300 (+4.28%) today
Regular session, Nov 10, 3:09 PM ET
- Market cap
- $463.99m
- P/E
- 18.7
- EPS, last 4 quarters
- $0.4300
- Dividend yield
- 3.24%
- Day range
- $7.90 to $8.14
- 52-week range
- $6.60 to $9.35
- Average volume
- 114.3k
- Previous close
- $7.71
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $13.33, +65.8% from here
Earnings
next estimate $0.1200Next report
Dec 2025
-33.3%
Mar 2026
-41.7%
Jun 2026
+33.3%
Sep 2026
+7.7%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- Kamada (KMDA) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- Kamada Q3 Earnings Call HighlightsMarketBeat · 1 day ago
- Kamada (KMDA) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks · 1 day ago
- Kamada (KMDA) Surpasses Q3 Earnings EstimatesZacks · 1 day ago
- Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass EstimatesZacks · 5 days ago
- Ahead of Kamada (KMDA) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsZacks · 5 days ago
- Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel GrowthMarketBeat · Sep 27, 2026
- Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase RTTNews · Sep 17, 2026
The company
Kamada Ltd. (the 'Company') is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company's strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF and HEPAGAM B, as well as KAMRAB, and two equine-based anti-snake venom products.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Middle East
- Website
- kamada.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.